ABCORFILM: Use of a New Method for the Microbiological Diagnosis of Severe Corneal Infection

Sponsor
CHU de Reims (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05888987
Collaborator
(none)
46
1
31
1.5

Study Details

Study Description

Brief Summary

Microbial keratitis is a severe and often blindness-inducing pathology which represents today the first reason for long-term hospitalization (more than 5 days) in ophthalmology. Its diagnosis is clinical and leads to an immediate hospitalization in the presence of serious criteria (Mackie classification). The entire process of microbiological diagnosis requires several days before etiological confirmation and therefore delays the initiation of targeted therapy.

Recently, new PCR systems allowing the detection of 18 to 27 pathogens in 75 minutes have been developed. Their use could thus be transposed to ophthalmology by adapting the microbiological diagnostic technique to samples currently taken by swabbing the cornea.

The investigators will compare their diagnosis performance versus conventional methods on patients who suffered for a microbial keratitis with severity criteria.

Condition or Disease Intervention/Treatment Phase
  • Biological: PCR multiplex by FilmArray

Detailed Description

46 patients enrolled for severe infectious keratitis will be recruited in the department of Ophthalmology, Robert Debré Hospital, Reims, France. The study will be composed by 2 groups. The first, also called "before group" will contain 23 patients who were anteriorly hospitalized for a severe infectious keratitis in our hospital unit. They received standard microbiological diagnosis methods: Direct microscopic examination with Gram stain, bacterial and fungal cultures, viral and amoebic polymerase chain reaction [PCR]).

The second, also called "after group" will enroll patients who suffer for a severe infectious keratitis (prospective group). Each patient will benefit a complete ophthalmologic examination, corneal scrapping and swabbing for standard microbiological diagnosis methods along with another corneal swabbing sample for the use of two different FilmArray® PCR systems identified as "ME" for Meningitis-Encephalitis and "BCID" for Blood Culture Identification.

The investigators hypothesize that the use of rapid multiplex PCR tests for the microbiological diagnosis of severe corneal infections could in the future prove to be more efficient than the current diagnostic strategy, on the one hand, by shortening the time to identify the pathogen and therefore to implement a targeted treatment, and on the other hand, by systematically searching for a large number of pathogens well beyond those targeted today. In addition, the benefits of this technique applied to ophthalmology could improve the long-term visual prognosis, reduce the length of hospitalization and therefore the diagnostic and management costs of these patients.

Study Design

Study Type:
Observational
Anticipated Enrollment :
46 participants
Observational Model:
Other
Time Perspective:
Other
Official Title:
Use of a New Rapid Multiplex PCR System for the Microbiological Diagnosis of Severe Infectious Keratitis: Impact on Therapeutic Management (ABCORFILM Study)
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2025
Anticipated Study Completion Date :
Jan 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Before

After

Biological: PCR multiplex by FilmArray
PCR multiplex by FilmArray system on corneal swabbing sample

Outcome Measures

Primary Outcome Measures

  1. Time to modification of the first line antimicrobial treatment towards a treatment targeting the detected pathogen. [At 2 weeks]

Secondary Outcome Measures

  1. Duration of hospitalization [At 1 month]

  2. Best corrected visual acuity [At 12 months]

  3. Modification of the initial antimicrobial treatment after detection of the etiological agent [At 1 month]

  4. Descriptive analysis of pathogens responsible for severe infectious keratitis in Champagne-Ardenne [At 1 month]

  5. • Costs of diagnostic methods (conventional and FilmArray) and management (cost of the average length of stay in ophthalmology at the Reims University Hospital for severe infectious keratitis) [At 1 month]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion criteria:
  • Over 18 years old

  • With social security affiliation

  • Willing to participate this study

  • Hospitalized in our department for severe infectious keratitis

Non-inclusion criteria:
  • Any prior (48 hours) or concomitant treatment with local or systemic antibiotherapy at time of corneal scrapping and swabbing

  • Patient not covered by the French Health Insurance

  • Unable to give informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Damien JOLLY Reims France

Sponsors and Collaborators

  • CHU de Reims

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
CHU de Reims
ClinicalTrials.gov Identifier:
NCT05888987
Other Study ID Numbers:
  • PA23064
First Posted:
Jun 5, 2023
Last Update Posted:
Jun 7, 2023
Last Verified:
May 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by CHU de Reims
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 7, 2023